echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > JCI: Study reveals relationship between psoriasis and joint disease

    JCI: Study reveals relationship between psoriasis and joint disease

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    June 10, 2020 /PRNewswire/ --- is well known that psoriasis is a chronic skin disease and there is no cureRecently, researchers at case Western Reserve University School of Medicine discovered an important pathogenesis of psoriasisThe researchers found that an excess of a protein called KLK6 produces and exacerbates, even more severe, skin inflammation in psoriasis;studies have also shown that normalizing LEVELs of KLK6 can eliminate skin inflammation and reduce arthritis-like damageThe study was published in the journal Journal of Clinical Investigation(photo:psoriasis is characterized by itchy red scaly plaquesThis chronic and incurable disease affects between 2 and 3 per cent of the world's populationAssociated psoriasis arthritis can cause bone and joint damageBecause the damage is irreversible, the researchers believe the key is to early diagnosis of patients with psoriasis arthritis to prevent further damage to their bones, tendons and joints, the authors conducted current studies to understand how the cell and molecular mechanisms of KLK6 and another protein called protease-activated receptor (PAR)1 contribute to the development of skin inflammationSo far, little is known about the link between KLK6 and psoriasis or psoriasis, and even less is known about PAR1 and psoriasis, said Ward, the author of the articleKLK6 controls the reaction son-in-the-cell (sometimes even outside the cell)There is growing scientific evidence that it may also play a role in certain inflammatory skin diseases as well as cancers, multiple sclerosis and Parkinson's and Alzheimer's diseasePAR1 is a receptor protein that receives chemical signals from outside the cell (e.g., KLK6), which in turn causes cell/tissue reactions, including inflammation, Ward and colleagues previously found that psoriasis patients had six times more KLK6 in their skin than normalThey also found that PAR1 receptors were produced excessively in the skin and immune cells Based on this, they reasoned that KLK6 may be used to signal the inflammation through PAR1 to solve this problem, the authors over-expression of KLK6 by genetically modified means, which led to psoriasis and bone and joint diseases in mice They also found that "knocking out" or removing PAR1 reduced skin inflammation and improved bone and joint diseases , the researchers then removed psoriasis skin from the patient and treated it in a petri dish with ANFDA-approved PAR1 antagonist drugs, which showed a significant reduction in several psoriasis markers next, the researchers looked at how inflammation of the skin can cause arthritis-like damage and used the findings to treat patients' diseases They also plan to study and compare models that can develop into or will not develop into arthritis to identify biomarkers that predict the development of psoriasis arthritis (Bio Valley Bioon.com) Source: Study-on-the-city-between psoriasis and original origin: J Clin Invest 2020; 130 (6): 3151-3157.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.